Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01083043 · ClinicalTrials.gov registry record
Continuous Glucose Monitoring in Type 2 Diabetes Mellitus
A clinical trial, sponsored by NYU Langone Health.
- Completed
- Registry status
- 28
- Enrollment target
NCT01083043: Completed study, sponsored by NYU Langone Health.
NCT01083043 is a clinical trial that has completed, run by NYU Langone Health. The registered enrollment target is 28 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01083043 has completed, sponsored by NYU Langone Health.
- COMPLETED
- Registry status
- 28 participants
- Enrollment target
Study Summary
It is well known that lowering average blood glucose decreases the risk of diabetic complications involving the small vessels, such as those found in the eyes, nerves and kidney. It is less clear however, if controlling fluctuations in blood glucose will further help to prevent such complications. The purpose of this study is to examine the relationship between extreme fluctuations in glucose and damage to the blood vessel lining.
Primary Outcome
The following biomarkers are studied: soluble e-selectin, vascular cell adhesion molecule-1, intercellular adhesion molecule-1 and asymmetric dimethylarginine. These analytes are highly correlated to endothelial dysfunction.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 28 participants |
| Start Date | 2006-12 |
| Est. Completion | 2011-03 |
What the finished NCT01083043 record still lists
NCT01083043 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 28 participants, a relatively small participant target.
The record links to 0 conditions, and to 0 interventions.
NCT01083043 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01083043 about?
NCT01083043 is a clinical study titled "Continuous Glucose Monitoring in Type 2 Diabetes Mellitus". It is well known that lowering average blood glucose decreases the risk of diabetic complications involving the small vessels, such as those found in the eyes, nerves and kidney. It is less clear however, if controlling fluctuations in blood glucose will further help to prevent such complications. ...
What is the current status of trial NCT01083043?
This trial is currently completed. The enrollment target is 28 participants. The study started on 2006-12. Estimated completion is 2011-03.
Who is sponsoring clinical trial NCT01083043?
This trial is sponsored by NYU Langone Health, which has 1,164 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03471117 · 28 participants · Phase 4
Pioglitazone to Reduce Sympathetic Overactivity in CKD Patients
- NCT03523975 · 28 participants · Phase 1
Venetoclax, Lenalidomide and Rituximab in Patients With Previously Untreated Mantle Cell Lymphoma
- NCT03608631 · 28 participants · Phase 1
iExosomes in Treating Participants With Metastatic Pancreas Cancer With KrasG12D Mutation
- NCT03810651 · 28 participants · Early Phase 1
Pencil Beam Scanning in Patients With Renal Tumors
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia